Navigation Links
New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
Date:5/15/2008

ecifically designed to target and

block the function of HER2, which causes fast growing, aggressive

breast cancer tumours. Herceptin delivers high cure rates for women

with HER2 positive early breast cancer and extends survival across all

stages of HER2 positive breast cancer by activating the immune system

and suppressing HER2. Herceptin is considered the foundation of care in

women with HER2-positive breast cancer and is recommended in treatment

guidelines throughout the world.

-- Colorectal cancer is the most common cancer in developed countries(4)

and the second most common cause of death from cancer across all cancer

types in men and women across Europe.(5)

-- Avastin acts by blocking VEGF, the key mediator of tumor angiogenesis,

offering patients a better chance of significantly improved survival.

Avastin is the first anti-angiogenic inhibitor to increase survival in

first and second line treatment and to provide significant improvements

in the time that patients can live without their disease advancing.

The 2008 ASCO Annual Meeting takes place from May 31 to June 3, McCormick Place, Chicago, Illinois, USA. Full details can be found at http://www.asco.org .

If you or your media colleagues are interested in attending the Roche Media Event during ASCO on 30th May, where the data outlined in brief above will be presented, please contact Anne Cameron (see details below).

References:

1. Wilking N and Jonsson B. A Pan-European comparison regarding patient

access to cancer drugs. Karolinska Institute in collaboration with

Stockholm School of Economics, Stockholm, Sweden, 2005

2. World Health Organisation (WHO) 2003.

http://www.who.int/mediacentre/releases/20
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
3. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
4. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
5. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
6. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
7. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
8. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
9. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
10. Roche responds to announcement of IDEAL hepatitis C trial results
11. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... DIEGO , July 30, 2015  Tandem ... medical device company and manufacturer of the t:slim® ... has entered into non-exclusive Development Agreements with Dexcom, ... Tandem insulin pumps with the Dexcom G5 and ... "Integrating Tandem,s next generation pump platform with Dexcom,s ...
(Date:7/30/2015)... July 30, 2015  Amgen (NASDAQ: AMGN ... quarter of 2015. Key results include: , ... quarter of 2014 to $5,370 million, with 6 ... ® (etanercept), Prolia ® (denosumab), Sensipar ... XGEVA ® (denosumab). Unfavorable changes in foreign ...
(Date:7/30/2015)... WOODCLIFF LAKE, N.J. , July 30, 2015 /PRNewswire/ ... submitted simultaneously in the United States ... (to the FDA, EMA and MHLW, respectively) for eribulin, ... sarcoma (STS) who have received prior chemotherapy for advanced ... are based on data from a pivotal global Phase ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... Argos Therapeutics, Inc. today announced that its late scientific co-founder ... Nobel Prize in medicine for the discovery of dendritic cells ... Steinman,s discovery of dendritic cells and his research of dendritic ... immunity have led to the development of Argos, core technology, ...
... Ingenious Med welcomes Chief Financial Officer, Mark Adams as ... responsible for the company,s financial, accounting, treasury and ongoing ... executive with high growth companies such as Ingenious Med," ... financial background and experience will bring tremendous value to ...
Cached Medicine Technology:Argos Therapeutics' Late Scientific Co-founder Ralph Steinman, M.D., Awarded Nobel Prize in Medicine for Discovery of Dendritic Cells as Critical Sentinels of Immune System 2New Chief Financial Officer, Mark Adams, Joins Ingenious Med 2
(Date:7/31/2015)... ... ... BioViva USA, Inc. (“BioViva”), a to-clinic gene therapy company based in Seattle, ... it has begun a fundraiser through Maximum Life Foundation (“MaxLife”) to use a promising ... will grant 100% of the money raised to BioViva to help bring pioneering gene ...
(Date:7/31/2015)... ... July 31, 2015 , ... Successful Import/Export Programs:, Former FDA ... , Having FDA-regulated products held at ports costs time, money and the competitive ... or even destruction — of products, an FDA insider shows manufacturers how to ...
(Date:7/31/2015)... ... July 31, 2015 , ... Florida Hospital ... catheter that was developed for targeted delivery of fluids to selected sites in ... at Florida Hospital Tampa with the device that provides direct, local delivery of ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reputable ... The U.S. Women's National Soccer Team will face the Australia Women's National Team in ... 17th at Ford Field in Detroit and the second match will occur in Birmingham, ...
(Date:7/31/2015)... ... July 31, 2015 , ... Indosoft, Inc., is pleased to ... Q-Suite 5.9. Q-Suite is their flagship contact center ACD system for Asterisk-based call ... display logic shows the script components to the agent only when wanted, and allows ...
Breaking Medicine News(10 mins):Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 2Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 4Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:Cheap USA vs. Australia Tickets at Legion Field in Birmingham, AL: Ticket Down Slashes Ticket Prices for Australia vs. USWNT at Legion Field 2Health News:Q-Suite 5.9 Adds Validation Tools to Call Center Software Agent Screen 2
... In a new study, researchers have discovered that suffering from ... which is a dangerous condition in which blood clots form ... cause an increase in the risk of heart attacks and ... of more than three million patient records from across the ...
... deal with crimes committed by drug addicts have been extended ... be started all across the country. // The drug courts ... 2002. These will undergo further monitoring by the Scottish Executive’s. ... indicated that there were no significant difference in re-conviction rates ...
... according to the decision taken by the Tibetan government in ... ,'Under an integrated development programme by 2007, $25 ... of the Tibetan government led by the Dalai Lama. ... India and some of them have taken around 20,000 acres ...
... of the brain plays an important role in distinguishing ... at the National Institutes of Health's (NIH) National Institute ... scans has found how the brain's outer layer, cortex, ... childhood stage, reflecting a high-level thinking circuitry. On the ...
... pain killing medication helps by halting the production of an ... cancer. The name of the painkiller is Nimesulide. // ... scientists found that derivatives of nimesulide stopped the production of ... of cancer is the most common breast cancer in postmenopausal ...
... Rudland, Dr Guozheng Wang and Dr Roger Barraclough from the ... new gene that causes the spread of cancer. // An ... is the main cause for the spread of cancerous cells ... If S100P is present it trigger the rapid spread of ...
Cached Medicine News:Health News:Cortex Of Youth With Superior IQ Matures Fast 2Health News:Pain-killer Drug Can Help Fight Breast Cancer 2
5.0% Casein digest (NZ amine), 2.5% Sodium Chloride, 2.5% Yeast Extract....
1.0% Casein digest (NZ amine), 0.5% Sodium Chloride, 0.5% Yeast Extract, 1.0% bacto casamino acids, 0.2% Mag. Sulfate....
0.5% Yeast Extract, 2.0% Tryp, 10mM Sodium Chloride, 2.5mM Potassium Chloride....
SOC Kit for Bacterial Cells containing 10 x 5mls Sterile growth medium with instructions...
Medicine Products: